Rifaximin on intestinally-related pathologic changes in sickle cell disease

Am J Hematol. 2020 Apr;95(4):E83-E86. doi: 10.1002/ajh.25722. Epub 2020 Feb 3.

Authors

Dibyendu Dutta¹, Kelvin Li², Barbara Methe², Seah H Lim^{1

3}

Affiliations

¹ Division of Hematology and Hemostasis, Department of Medicine, New York Medical College, Valhalla, New York.
² Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania.
³ Westchester Medical Center Cancer Institute, Hawthorne, New York.

PMID: 31925798
DOI: 10.1002/ajh.25722

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Abdominal Pain / etiology*
Abdominal Pain / prevention & control
Anemia, Sickle Cell / complications*
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Bacterial Translocation / drug effects
Biomarkers
Dysbiosis / blood
Dysbiosis / drug therapy*
Dysbiosis / etiology
Dysbiosis / urine
Gastrointestinal Agents / pharmacology
Gastrointestinal Agents / therapeutic use*
Gastrointestinal Microbiome / drug effects*
Humans
Indican / urine
L-Selectin / blood
Neutrophil Activation / drug effects*
Rifaximin / pharmacology
Rifaximin / therapeutic use*

Substances

Anti-Bacterial Agents
Biomarkers
Gastrointestinal Agents
SELL protein, human
L-Selectin
Rifaximin
Indican